Sarador, Joana Rose .
HRN: 02-84-87 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/10/2022
CO-AMOXICLAV 625MG (TAB)
07/10/2022
07/17/2022
PO
625
Q12H
S/P NSVD W/RMLE MSAF
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes